Prilenia is dedicated to developing new treatments for the urgent needs facing patients and families with Huntington’s disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases and neurodevelopmental disorders.

As we study pridopidine for multiple diseases that originate in the brain, we are uncovering new possibilities and driving research forward to give patients and their families hope.

Compelling scientific findings show activation of the sigma-1 receptor (S1R) restores pathways in the brain impaired by neurodegenerative diseases.

Learn more about Prilenia’s pipeline, scientific progress, and growing business.

We are aiming to change the lives of patients and their families. Passion, imagination, and innovation make a difference. We need people who are ready to think creatively, collaborate, and do more. If that’s you, let’s talk about working together.

Founded in 2018 by Michael Hayden, MBChB, PhD, a world-renowned scientist in Huntington’s disease (HD) research, Prilenia is a clinical-stage biotech company focused on the urgent mission of developing novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders. The company is led by a highly experienced team of visionary scientists, drug developers, and business leaders with a proven track record of success. The team is deeply committed to scientific excellence and providing hope to patients, families, and caregivers around the globe.

The company’s most recent financing was a Series B in 2022 and is backed by a group of well-respected investors, including Forbion, Morningside Venture Investments, Sands Capital, Sectoral Asset Management, Talisman Capital Partners, SV Health Investors, Amplitude Ventures, and the ALS Investment Fund. Prilenia is a global company with offices in Naarden, the Netherlands, Yakum, Israel, and Waltham, Massachusetts, United States.

Pridopidine, an investigational product, is an oral, highly selective and potent sigma-1 receptor (S1R) agonist with an established safety profile.

Pridopidine is currently in late-stage clinical development for HD and amyotrophic lateral sclerosis (ALS).